🔗 Share this article

Given that America proceeds with historic adjustments to its vaccine recommendations, one figure has surfaced unexpectedly: Høeg, a US-based physician and epidemiologist who initially gained attention by questioning Covid vaccinations throughout the global health crisis and has focused upon possible deaths after Covid immunization in her brief position at the US Food and Drug Administration (FDA).

Scheduled Shifts to Pediatric Immunization Schedule

Public health authorities were set to unveil radical revisions to the pediatric vaccine schedule in December, synchronizing the US with Denmark’s immunization schedule, it is understood – a significant shift that would place the US out of alignment with much of the international standard with little proof for benefit. The planned update has been pushed back until the coming year.

Rather than the top vaccines chief, Høeg is set to speak at the event. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the division this year.

Consolidating Power at the FDA

The acting appointment might represent a closer partnership between the drug and vaccine branches as Høeg and Dr. Prasad strengthen their influence at the agency – and it points to a renewed priority upon reevaluating already-approved vaccines at the FDA.

The new acting director has frequently advocated for discontinuing some pediatric immunization guidelines in the US so as to align more like Denmark's approach, a nation with nationalized medicine and a number of inhabitants about the size of the state of Wisconsin.

To date comments, she has kept her attention on vaccines – usually the domain of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Doubts Over Expertise

Høeg has little discernible experience in drug development, oversight or leadership, which has been typical for former heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“It seems she lacks to have the requisite experience” for leading the drug-regulation department, said Dr. Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in running a sizeable institution. She is not an expert in pharmaceutical oversight.”

Former heads of CBER would “grasp regulatory frameworks and the research of medication creation”, commented Dr. Janet Woodcock. “Objectively, she has not acquired the kind of background that previous people who ran CBER have had.”

CDER has an immense workload at the agency, she emphasized.

“Everybody just pays attention on the novel medication approvals, but the off-patent medication office approves thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and other areas, and all of those must be supervised,” Woodcock explained. “The thing you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a significant management aspect to the job, which manages over 5,000 employees. “It’s a huge management job, if you perform it correctly,” the former official concluded.

Response and Disputed Programs

Regarding inquiries about Høeg’s credentials and whether this appointment signifies more teamwork among FDA leaders on vaccines, a representative said that the “questions stem from incorrect premises”.

“This background matches the responsibilities of her role,” the official stated, noting the period Høeg spent advising the agency head on “pharmaceutical safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's new expedited review system, a disputed one-day medication authorization process that allegedly troubled her preceding directors. “How are these drugs being picked for this expedited pathway? Who takes the calls?” Dr. Howard said. “There is a lot of confidentiality going on at the agency right now.”

Overall, he stated, “the FDA seems to be moving towards more relaxed oversight of pharmaceuticals, aside from shots.”

Established History on Immunizations

Regarding immunizations, Dr. Høeg has a clearer, if troubling, history, critics said. She published a study using unconfirmed volunteer-provided data to assess the rate of myocarditis after Covid immunization. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccines are pose a greater threat than they are.

Part of her “policy goals” for the new federal leadership featured altering rules for novel immunizations and discontinuing “non-essential” vaccines, she stated after the election on a audio program. At the agency, Dr. Høeg has allegedly suggested excluding young men from getting COVID-19 vaccines.

“She is an all-around dogmatist who starts off with her conclusions and works backwards to retrofit the data in a very disingenuous, dishonest manner,” Dr. Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg joined other dissenters, {like|